IL100432A - Dihydrobenzopuran carboxamides, their preparation and pharmaceutical preparations containing them - Google Patents
Dihydrobenzopuran carboxamides, their preparation and pharmaceutical preparations containing themInfo
- Publication number
- IL100432A IL100432A IL10043291A IL10043291A IL100432A IL 100432 A IL100432 A IL 100432A IL 10043291 A IL10043291 A IL 10043291A IL 10043291 A IL10043291 A IL 10043291A IL 100432 A IL100432 A IL 100432A
- Authority
- IL
- Israel
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- azabicyclo
- methyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 title description 6
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 69
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 125000001424 substituent group Chemical group 0.000 claims abstract description 5
- 208000002193 Pain Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 208000035475 disorder Diseases 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
- 239000001257 hydrogen Substances 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 4
- 241000124008 Mammalia Species 0.000 claims abstract description 3
- 206010047700 Vomiting Diseases 0.000 claims abstract description 3
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 3
- 230000010243 gut motility Effects 0.000 claims abstract description 3
- 208000019695 Migraine disease Diseases 0.000 claims abstract 2
- 206010027599 migraine Diseases 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 3
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 3
- 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- UNOGKRAUCNKBGO-UHFFFAOYSA-N 4-amino-n-(1-azabicyclo[3.3.1]nonan-4-yl)-5-chloro-2,3-dihydro-1-benzofuran-7-carboxamide Chemical compound C1CN(C2)CCCC2C1NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1 UNOGKRAUCNKBGO-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- -1 for example Substances 0.000 description 6
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 5
- 229960005343 ondansetron Drugs 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000035037 5-HT3 receptors Human genes 0.000 description 3
- 108091005477 5-HT3 receptors Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 3
- 229960004503 metoclopramide Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- HDDNYFLPWFSBLN-ZSHCYNCHSA-N tropanyl 3,5-dimethylbenzoate Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(C)=CC(C)=C1 HDDNYFLPWFSBLN-ZSHCYNCHSA-N 0.000 description 3
- HJGMRAKQWLKWMH-IEESLHIDSA-N (1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine Chemical compound C1C(N)C[C@@]2([H])CC[C@]1([H])N2C HJGMRAKQWLKWMH-IEESLHIDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012050 conventional carrier Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- KRMUVKSAOVLXLF-UHFFFAOYSA-N 4-amino-5-chloro-2,3-dihydro-1-benzofuran-7-carboxylic acid Chemical compound C1=C(Cl)C(N)=C2CCOC2=C1C(O)=O KRMUVKSAOVLXLF-UHFFFAOYSA-N 0.000 description 1
- ZDEFECMXFAXFEJ-UHFFFAOYSA-N 4-amino-5-chloro-n-(2-methyl-2-azabicyclo[2.2.2]octan-5-yl)-2,3-dihydro-1-benzofuran-7-carboxamide Chemical compound CN1CC2CCC1CC2NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2 ZDEFECMXFAXFEJ-UHFFFAOYSA-N 0.000 description 1
- DWZQSTFWTQSETL-UHFFFAOYSA-N 4-amino-5-chloro-n-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-2,3-dihydro-1-benzofuran-7-carboxamide Chemical compound CN1C(C2)CCC1CC2NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2 DWZQSTFWTQSETL-UHFFFAOYSA-N 0.000 description 1
- FTLJDTJGHVSPBU-UHFFFAOYSA-N 4-amino-5-chloro-n-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-2,3-dihydro-1-benzofuran-7-carboxamide Chemical compound CN1C(C2)CCCC1CC2NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2 FTLJDTJGHVSPBU-UHFFFAOYSA-N 0.000 description 1
- HTZWHTQVHWHSHN-UHFFFAOYSA-N 9-methyl-9-azabicyclo[3.3.1]nonan-3-amine Chemical compound C1CCC2CC(N)CC1N2C HTZWHTQVHWHSHN-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 101000837626 Homo sapiens Thyroid hormone receptor alpha Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909028104A GB9028104D0 (en) | 1990-12-27 | 1990-12-27 | Dihydrobenzofuran carboxamides and process for their preparation |
| GB919107140A GB9107140D0 (en) | 1991-04-05 | 1991-04-05 | Dihydrobenzofuran carboxamides and process for their preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL100432A0 IL100432A0 (en) | 1992-09-06 |
| IL100432A true IL100432A (en) | 1996-01-19 |
Family
ID=26298184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10043291A IL100432A (en) | 1990-12-27 | 1991-12-19 | Dihydrobenzopuran carboxamides, their preparation and pharmaceutical preparations containing them |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5362740A (pt) |
| EP (1) | EP0493031B1 (pt) |
| JP (1) | JP3453394B2 (pt) |
| KR (1) | KR920012083A (pt) |
| AT (1) | ATE127119T1 (pt) |
| AU (1) | AU638665B2 (pt) |
| CA (1) | CA2058264C (pt) |
| DE (1) | DE69112594T2 (pt) |
| DK (1) | DK0493031T3 (pt) |
| ES (1) | ES2079590T3 (pt) |
| FI (1) | FI97806C (pt) |
| GR (1) | GR3017872T3 (pt) |
| HU (1) | HU208538B (pt) |
| IE (1) | IE914488A1 (pt) |
| IL (1) | IL100432A (pt) |
| MX (1) | MX9102686A (pt) |
| NZ (1) | NZ241067A (pt) |
| PT (1) | PT99886B (pt) |
| TW (1) | TW242624B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9028105D0 (en) * | 1990-12-27 | 1991-02-13 | Erba Carlo Spa | Process for the preparation of substituted benzofuran derivatives |
| JP2999669B2 (ja) * | 1993-08-24 | 2000-01-17 | 株式会社三和化学研究所 | ベンゾ［ｂ］フランカルボキサミド誘導体、その製法及び用途 |
| JPH0820586A (ja) * | 1994-07-05 | 1996-01-23 | Sanwa Kagaku Kenkyusho Co Ltd | １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途 |
| JPH0873463A (ja) | 1994-07-05 | 1996-03-19 | Sanwa Kagaku Kenkyusho Co Ltd | ベンゾピランカルボキサミド誘導体、その塩及び製法並びに用途 |
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| AR036041A1 (es) * | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| BR0212477A (pt) * | 2001-09-12 | 2004-08-24 | Upjohn Co | 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças |
| PL369895A1 (en) | 2001-10-02 | 2005-05-02 | Pharmacia & Upjohn Company | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
| EP1442037A1 (en) | 2001-11-09 | 2004-08-04 | PHARMACIA & UPJOHN COMPANY | Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands |
| WO2003070731A2 (en) * | 2002-02-19 | 2003-08-28 | Pharmacia & Upjohn Company | Azabicyclic compounds for the treatment of disease |
| JP2005523288A (ja) * | 2002-02-19 | 2005-08-04 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド |
| CA2503786A1 (en) * | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Compounds having both alpha7 nicotinic agonist activity and 5ht, antagonist activity for treatment of cns diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3705165A (en) * | 1970-08-05 | 1972-12-05 | Elmar Sturm | N-carbonyl derivatives of azabicyclooctanes |
| GB1593146A (en) * | 1976-11-05 | 1981-07-15 | Beecham Group Ltd | Octahydro-quinolizinyl benzamide derivatives |
| IL59004A0 (en) * | 1978-12-30 | 1980-03-31 | Beecham Group Ltd | Substituted benzamides their preparation and pharmaceutical compositions containing them |
| US4350691A (en) * | 1979-12-20 | 1982-09-21 | Beecham Group Limited | Certain azabicyclocarboxamides and compositions containing same |
| EP0099194A3 (en) * | 1982-07-03 | 1984-04-11 | Beecham Group Plc | Novel benzamides |
| EP0135545A1 (en) * | 1983-02-19 | 1985-04-03 | Beecham Group Plc | Azabicycloalkyl benzamide and anilide derivatives |
| US4888353A (en) * | 1986-02-28 | 1989-12-19 | Erbamont, Inc. | Carboxamides useful as antiemetic or antipsychotic agents |
| GB8718345D0 (en) * | 1987-08-03 | 1987-09-09 | Fordonal Sa | N-substituted benzamides |
| US4921982A (en) * | 1988-07-21 | 1990-05-01 | Eli Lilly And Company | 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists |
| US4997956A (en) * | 1989-06-14 | 1991-03-05 | Eli Lilly And Company | Certain 2,3-dihydro-2;2-dimethyl-benzothiophene carboxylic acids which are intermediates |
| US4863921A (en) * | 1988-04-27 | 1989-09-05 | Rorer Pharmaceutical Corporation | Dibenzofurancarboxamides and their pharmaceutical compositions and methods |
| JPH0232077A (ja) * | 1989-06-16 | 1990-02-01 | Yoshitomi Pharmaceut Ind Ltd | ベンゾフランおよびベンゾピラン化合物 |
| GB9028105D0 (en) * | 1990-12-27 | 1991-02-13 | Erba Carlo Spa | Process for the preparation of substituted benzofuran derivatives |
-
1991
- 1991-12-19 IL IL10043291A patent/IL100432A/en not_active IP Right Cessation
- 1991-12-19 MX MX9102686A patent/MX9102686A/es not_active IP Right Cessation
- 1991-12-19 NZ NZ241067A patent/NZ241067A/en unknown
- 1991-12-20 FI FI916058A patent/FI97806C/fi not_active IP Right Cessation
- 1991-12-20 DE DE69112594T patent/DE69112594T2/de not_active Expired - Fee Related
- 1991-12-20 CA CA002058264A patent/CA2058264C/en not_active Expired - Fee Related
- 1991-12-20 EP EP91311886A patent/EP0493031B1/en not_active Expired - Lifetime
- 1991-12-20 TW TW080110003A patent/TW242624B/zh active
- 1991-12-20 AT AT91311886T patent/ATE127119T1/de not_active IP Right Cessation
- 1991-12-20 DK DK91311886.5T patent/DK0493031T3/da active
- 1991-12-20 IE IE448891A patent/IE914488A1/en unknown
- 1991-12-20 AU AU89958/91A patent/AU638665B2/en not_active Ceased
- 1991-12-20 PT PT99886A patent/PT99886B/pt not_active IP Right Cessation
- 1991-12-20 HU HU914093A patent/HU208538B/hu not_active IP Right Cessation
- 1991-12-20 ES ES91311886T patent/ES2079590T3/es not_active Expired - Lifetime
- 1991-12-23 KR KR1019910023918A patent/KR920012083A/ko not_active Application Discontinuation
- 1991-12-24 JP JP34146791A patent/JP3453394B2/ja not_active Expired - Fee Related
-
1992
- 1992-11-30 US US07/983,274 patent/US5362740A/en not_active Expired - Lifetime
-
1995
- 1995-10-25 GR GR950402976T patent/GR3017872T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE127119T1 (de) | 1995-09-15 |
| CA2058264C (en) | 1999-03-16 |
| EP0493031A1 (en) | 1992-07-01 |
| FI97806C (fi) | 1997-02-25 |
| JPH04295476A (ja) | 1992-10-20 |
| DK0493031T3 (da) | 1995-09-25 |
| KR920012083A (ko) | 1992-07-25 |
| CA2058264A1 (en) | 1992-06-28 |
| DE69112594T2 (de) | 1996-02-01 |
| AU638665B2 (en) | 1993-07-01 |
| GR3017872T3 (en) | 1996-01-31 |
| FI916058A (fi) | 1992-06-28 |
| FI916058A0 (fi) | 1991-12-20 |
| EP0493031B1 (en) | 1995-08-30 |
| US5362740A (en) | 1994-11-08 |
| AU8995891A (en) | 1992-07-02 |
| JP3453394B2 (ja) | 2003-10-06 |
| TW242624B (pt) | 1995-03-11 |
| HUT59678A (en) | 1992-06-29 |
| FI97806B (fi) | 1996-11-15 |
| ES2079590T3 (es) | 1996-01-16 |
| PT99886A (pt) | 1992-12-31 |
| HU208538B (en) | 1993-11-29 |
| DE69112594D1 (de) | 1995-10-05 |
| IE914488A1 (en) | 1992-07-01 |
| MX9102686A (es) | 1994-01-31 |
| PT99886B (pt) | 1999-06-30 |
| IL100432A0 (en) | 1992-09-06 |
| NZ241067A (en) | 1993-03-26 |
| HU914093D0 (en) | 1992-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4789673A (en) | Heterocyclic carboxylic acid amides and esters | |
| EP0469449A1 (en) | Azabicyclo derivatives | |
| GB2236751A (en) | 4-Oxo-quinolines and chromones | |
| IL100432A (en) | Dihydrobenzopuran carboxamides, their preparation and pharmaceutical preparations containing them | |
| JP2643274B2 (ja) | イミダゾ〔１，２−ａ〕ピリジン誘導体 | |
| EP0505778B1 (en) | Derivatives of substituted imidazol-2-one and process for their preparation | |
| EP0711299B1 (en) | AZABICYCLOALKYL DERIVATIVES OF IMIDAZO(1,5-a)INDOL-3-ONE AS 5HT 3 ANTAGONISTS | |
| NZ241019A (en) | Azabicyclic-substituted benzoic acid or benzamide derivatives and pharmaceutical compositions | |
| EP1018512B1 (en) | Novel basic derivatives of benz(e)isoindol-1-ones and pyrrolo(3,4-c)quinolin-1-ones with 5-HT3-antagonistic activity, their preparation and their therapeutic use | |
| NZ240938A (en) | Azabicyclic-substituted benzodioxans and analogues; pharmaceutical compositions thereof | |
| US5364854A (en) | Derivatives of substituted imidazo benzoxazin-1-one and process for their preparation | |
| RU2043991C1 (ru) | Дигидробензофурановые карбоксамиды или его фармацевтически приемлемые соли и способ их получения | |
| WO1995032204A1 (en) | Imidazolylalkyl derivatives of imidazo(1,5-a)indol-3-one and their use as therapeutic agents | |
| GB2269747A (en) | A pharmaceutical aroyl-urea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| HC | Change of name of proprietor(s) | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |